Identification

Name
Bisoprolol
Accession Number
DB00612  (APRD00257)
Type
Small Molecule
Groups
Approved
Description

Bisoprolol is a cardioselective β1-adrenergic blocking agent used for secondary prevention of myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. Bisoprolol is structurally similar to metoprolol, acebutolol and atenolol in that it has two substituents in the para position of the benzene ring. The β1-selectivity of these agents is thought to be due in part to the large substituents in the para position. At lower doses (less than 20 mg daily), bisoprolol selectively blocks cardiac β1-adrenergic receptors with little activity against β2-adrenergic receptors of the lungs and vascular smooth muscle. Receptor selectivity decreases with daily doses of 20 mg or greater. Unlike propranolol and pindolol, bisoprolol does not exhibit membrane-stabilizing or sympathomimetic activity. Bisoprolol possesses a single chiral centre and is administered as a racemic mixture. Only l-bisoprolol exhibits significant β-blocking activity.

Structure
Thumb
Synonyms
  • (+-)-1-((alpha-(2-Isopropoxyethoxy)-P-tolyl)oxy)-3-(isopropylamino)-2-propanol
  • (RS)-1-(4-(2-isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol
  • Bisoprolol
  • Bisoprololum
External IDs
CL 297939 / EMD 33512
Product Ingredients
IngredientUNIICASInChI Key
Bisoprolol FumarateUR59KN573L104344-23-2VMDFASMUILANOL-WXXKFALUSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-bisoprololTablet5 mgOralAvanstra Inc2011-08-222014-08-21Canada
Ava-bisoprololTablet10 mgOralAvanstra Inc2011-08-222014-08-21Canada
BisoprololTablet5 mgOralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
BisoprololTablet10 mgOralSorres Pharma Inc2009-02-262014-06-20Canada
BisoprololTablet10 mgOralSanis Health Inc2012-10-01Not applicableCanada
BisoprololTablet10 mgOralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
BisoprololTablet5 mgOralSanis Health Inc2012-10-01Not applicableCanada
BisoprololTablet5 mgOralSorres Pharma Inc2009-02-262014-06-20Canada
Dom-bisoprololTablet5 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-bisoprololTablet10 mgOralDominion PharmacalNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-bisoprololTablet10 mgOralApotex Corporation2004-08-10Not applicableCanada
Apo-bisoprololTablet5 mgOralApotex Corporation2004-08-10Not applicableCanada
Bisoprolol FumarateTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2009-07-23Not applicableUs
Bisoprolol FumarateTablet5 mg/1OralProficient Rx LP2009-09-21Not applicableUs
Bisoprolol FumarateTablet, film coated5 mg/1OralAurobindo Pharma2006-12-27Not applicableUs
Bisoprolol FumarateTablet, film coated10 mg/1OralMylan Pharmaceuticals2012-09-24Not applicableUs
Bisoprolol FumarateTablet, film coated10 mg/1OralCitron Pharma LLC2006-12-27Not applicableUs
Bisoprolol FumarateTablet, film coated5 mg/1OralTeva2004-06-01Not applicableUs
Bisoprolol FumarateTablet10 mg/1OralUnichem Pharmaceuticals (USA), Inc.2009-09-21Not applicableUs
Bisoprolol FumarateTablet, coated10 mg/1OralEon Labs, Inc.2000-11-16Not applicableUs
International/Other Brands
Cardicor (Bayer) / Concor (Merck) / Concore (Merck) / Detensiel (Merck Santé) / Emconcor (Merck) / Emcor (Merck) / Euradal (Lacer) / Isoten (Meda) / Monocor (Biovail Pharmaceuticals) / Soprol (Helsinn)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Bisoprolol Fumarate and HydrochlorothiazideBisoprolol Fumarate (10 mg/1) + Hydrochlorothiazide (6.25 mg/1)TabletOralA S Medication Solutions2010-10-12Not applicableUs
Bisoprolol Fumarate and HydrochlorothiazideBisoprolol Fumarate (5 mg/1) + Hydrochlorothiazide (6.25 mg/1)Tablet, coatedOralEon Labs, Inc.2000-09-25Not applicableUs
Bisoprolol Fumarate and HydrochlorothiazideBisoprolol Fumarate (5 mg/1) + Hydrochlorothiazide (6.25 mg/1)TabletOralAidarex Pharmaceuticals LLC2010-10-12Not applicableUs
Bisoprolol Fumarate and HydrochlorothiazideBisoprolol Fumarate (10 mg/1) + Hydrochlorothiazide (6.25 mg/1)Tablet, coatedOralbryant ranch prepack2000-09-25Not applicableUs
Bisoprolol Fumarate and HydrochlorothiazideBisoprolol Fumarate (5 mg/1) + Hydrochlorothiazide (6.25 mg/1)Tablet, coatedOralRebel Distributors2000-09-25Not applicableUs
Bisoprolol Fumarate and HydrochlorothiazideBisoprolol Fumarate (10 mg/1) + Hydrochlorothiazide (6.25 mg/1)Tablet, film coatedOralbryant ranch prepack2011-10-03Not applicableUs00378 0505 01 nlmimage10 652332f9
Bisoprolol Fumarate and HydrochlorothiazideBisoprolol Fumarate (5 mg/1) + Hydrochlorothiazide (6.25 mg/1)TabletOralUnichem Pharmaceuticals (USA), Inc.2010-10-12Not applicableUs
Bisoprolol Fumarate and HydrochlorothiazideBisoprolol Fumarate (5 mg/1) + Hydrochlorothiazide (6.25 mg/1)Tablet, film coatedOralMylan Pharmaceuticals2000-09-25Not applicableUs00378 0503 01 nlmimage10 c923e4bf
Bisoprolol Fumarate and HydrochlorothiazideBisoprolol Fumarate (2.5 mg/1) + Hydrochlorothiazide (6.25 mg/1)Tablet, coatedOralEon Labs, Inc.2000-09-25Not applicableUs
Bisoprolol Fumarate and HydrochlorothiazideBisoprolol Fumarate (2.5 mg/1) + Hydrochlorothiazide (6.25 mg/1)TabletOralA S Medication Solutions2010-10-12Not applicableUs
Categories
UNII
Y41JS2NL6U
CAS number
66722-44-9
Weight
Average: 325.443
Monoisotopic: 325.225308485
Chemical Formula
C18H31NO4
InChI Key
VHYCDWMUTMEGQY-UHFFFAOYSA-N
InChI
InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3
IUPAC Name
1-[(propan-2-yl)amino]-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1

Pharmacology

Indication

For management of heart failure, angina pectoris, and mild to moderate hypertension and for secondary prevention of myocardial infarction (MI).

Structured Indications
Pharmacodynamics

Bisoprolol is a competitive, cardioselective β1-adrenergic antagonist. Activation of β1-receptors (located mainly in the heart) by epinephrine increases heart rate and the blood pressure causing the heart to consume more oxygen. β1-adrenergic blocking agents such as bisopolol lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. They are routinely prescribed in patients with ischemic heart disease. In addition, β1-selective blockers prevent the release of renin, a hormone produced by the kidneys causes constriction of blood vessels. Bisoprolol is lipophilic and exhibits no intrinsic sympathomimetic activity (ISA) or membrane-stabilizing activity.

Mechanism of action

Bisoprolol selectively blocks catecholamine stimulation of β1-adrenergic receptors in the heart and vascular smooth muscle. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. At higher doses (e.g. 20 mg and greater) bisoprolol may competitively block β2-adrenergic receptors in bronchial and vascular smooth muscle causing bronchospasm and vasodilation.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
NBeta-2 adrenergic receptor
antagonist
Human
Absorption

Well absorbed. Bioavailability > 80%. Absorption is not affected by food. Peak plasma concentrations occur within 2-4 hours.

Volume of distribution
Not Available
Protein binding

Binding to serum proteins is approximately 30%

Metabolism

Approximately 50% of the dose is metabolized primarily metabolized by CYP3A4 to inactive metabolites. In vitro studies have shown that bisoprolol is also metabolized by CYP2D6 though this does not appear to be clinically significant. Approximately half the administered dose is excreted in unchanged in urine.

Route of elimination

Eliminated equally by renal and non-renal pathways. Approximately 50% of the total orally administered dose is excreted unchanged in urine with the remainder appearing as inactive metabolites. Less than 2% of the dose is excreted in the feces.

Half life

9-12 hours; prolonged in the elderly and those with decreased renal function

Clearance
Not Available
Toxicity

Oral, mouse: LD50 = 100 mg/kg; Skin, rabbit: LD50 = 200 mg/kg; Skin, rat: LD50 = 500 mg/kg. Symptoms of overdose include congestive heart failure (marked by sudden weight gain, swelling of the legs, feet, and ankles, fatigue, and shortness of breath), difficult or labored breathing, low blood pressure, low blood sugar, and slow heartbeat.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Bisoprolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bisoprolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bisoprolol.Experimental
AbirateroneThe serum concentration of Bisoprolol can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Bisoprolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Bisoprolol.Approved
AcetohexamideBisoprolol may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Acetylcholine.Approved
AcetyldigitoxinBisoprolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinBisoprolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Bisoprolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Experimental, Investigational
AlaproclateThe serum concentration of Bisoprolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Bisoprolol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bisoprolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Bisoprolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Bisoprolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Bisoprolol.Experimental
AlprenololBisoprolol may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Bisoprolol.Approved
AmbrisentanBisoprolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateBisoprolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental, Investigational
AmifostineBisoprolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Bisoprolol.Approved
AminophyllineBisoprolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Bisoprolol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bisoprolol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Bisoprolol.Approved, Illicit
AmodiaquineThe metabolism of Bisoprolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Bisoprolol.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bisoprolol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Bisoprolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Bisoprolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Bisoprolol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Bisoprolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
AprepitantThe serum concentration of Bisoprolol can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineBisoprolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Arecoline.Experimental
ArformoterolBisoprolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Bisoprolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bisoprolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bisoprolol.Approved, Investigational
ArtemetherThe metabolism of Bisoprolol can be decreased when combined with Artemether.Approved
AtazanavirThe metabolism of Bisoprolol can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Bisoprolol.Approved
AtomoxetineThe metabolism of Bisoprolol can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Bisoprolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bisoprolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Bisoprolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
BambuterolBisoprolol may decrease the bronchodilatory activities of Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Bisoprolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Bisoprolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Bisoprolol.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Bisoprolol.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Bisoprolol.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Bisoprolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Bisoprolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Bisoprolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bisoprolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Bisoprolol.Approved
BepridilBisoprolol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantBisoprolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Bisoprolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Bisoprolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Bisoprolol.Experimental
BimatoprostBisoprolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BL-1020BL-1020 may increase the hypotensive activities of Bisoprolol.Investigational
BoceprevirThe metabolism of Bisoprolol can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Bisoprolol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bisoprolol can be decreased when it is combined with Bosentan.Approved, Investigational
BQ-123Bisoprolol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the bradycardic activities of Bisoprolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Bisoprolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Bisoprolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Bisoprolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Bisoprolol.Investigational
BucindololBisoprolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Bisoprolol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Bisoprolol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Bumetanide.Approved
BunazosinBisoprolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bisoprolol.Approved, Investigational
BupranololBisoprolol may increase the hypotensive activities of Bupranolol.Approved
BupropionThe metabolism of Bisoprolol can be decreased when combined with Bupropion.Approved
CabergolineBisoprolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Bisoprolol.Experimental
CafedrineBisoprolol may increase the hypotensive activities of Cafedrine.Investigational
CalfactantBisoprolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Canagliflozin.Approved
CandesartanBisoprolol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Candesartan cilexetil.Approved
CandoxatrilBisoprolol may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Carbachol.Approved
CarbamazepineThe metabolism of Bisoprolol can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Bisoprolol.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Bisoprolol.Approved
CarbutamideBisoprolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Bisoprolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Bisoprolol.Approved
CarvedilolBisoprolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Bisoprolol.Experimental
CelecoxibThe metabolism of Bisoprolol can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololBisoprolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Bisoprolol can be increased when it is combined with Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Bisoprolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Chlorothiazide.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Bisoprolol.Experimental
ChlorpromazineThe metabolism of Bisoprolol can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideBisoprolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bisoprolol.Approved
CholecalciferolThe metabolism of Bisoprolol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Bisoprolol.Approved
CicletanineBisoprolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Bisoprolol.Approved, Investigational
CimetidineThe metabolism of Bisoprolol can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Bisoprolol can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Bisoprolol can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Bisoprolol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Bisoprolol can be decreased when combined with Clemastine.Approved
ClenbuterolBisoprolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Clevidipine.Approved
ClobazamThe metabolism of Bisoprolol can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Bisoprolol.Approved, Investigational
ClomipramineThe metabolism of Bisoprolol can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Bisoprolol.Approved
CloranololBisoprolol may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Bisoprolol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Bisoprolol can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Bisoprolol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Bisoprolol can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Bisoprolol can be increased when it is combined with Conivaptan.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Bisoprolol.Vet Approved
CrizotinibThe metabolism of Bisoprolol can be decreased when combined with Crizotinib.Approved
CryptenamineBisoprolol may increase the hypotensive activities of Cryptenamine.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Bisoprolol.Investigational
CyclopenthiazideBisoprolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Bisoprolol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Bisoprolol.Approved
CymarinBisoprolol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Bisoprolol.Investigational
DabrafenibThe serum concentration of Bisoprolol can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Bisoprolol can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Bisoprolol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Bisoprolol can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Bisoprolol can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Bisoprolol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Bisoprolol.Approved
DeferasiroxThe serum concentration of Bisoprolol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilBisoprolol may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Bisoprolol can be decreased when combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Bisoprolol.Approved
DeserpidineBisoprolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Bisoprolol.Approved
DesipramineThe metabolism of Bisoprolol can be decreased when combined with Desipramine.Approved
DeslanosideBisoprolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Bisoprolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Bisoprolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Bisoprolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Diclofenamide.Approved
diethylnorspermineBisoprolol may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Bisoprolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Bisoprolol.Approved
DigitoxinBisoprolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinDigoxin may increase the bradycardic activities of Bisoprolol.Approved
Digoxin Immune Fab (Ovine)Bisoprolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Bisoprolol.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Bisoprolol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Bisoprolol can be decreased when combined with Diphenhydramine.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Bisoprolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Bisoprolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Bisoprolol.Experimental
DobutamineBisoprolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Bisoprolol.Approved
DorzolamideBisoprolol may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe metabolism of Bisoprolol can be decreased when combined with Dosulepin.Approved
DoxazosinBisoprolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxycyclineThe metabolism of Bisoprolol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneDronedarone may increase the bradycardic activities of Bisoprolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Bisoprolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational
DuloxetineBisoprolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Bisoprolol.Investigational
DyphyllineBisoprolol may decrease the bronchodilatory activities of Dyphylline.Approved
E-6201E-6201 may decrease the antihypertensive activities of Bisoprolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Bisoprolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Bisoprolol.Approved
EfonidipineBisoprolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
EliglustatThe metabolism of Bisoprolol can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Bisoprolol.Approved, Vet Approved
EnalaprilatBisoprolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Bisoprolol.Experimental
EnzalutamideThe serum concentration of Bisoprolol can be decreased when it is combined with Enzalutamide.Approved
EpanololBisoprolol may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Bisoprolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Eplerenone.Approved
EpoprostenolBisoprolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Eprosartan.Approved
Ergoloid mesylateBisoprolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineBisoprolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
ErythromycinThe metabolism of Bisoprolol can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Bisoprolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Bisoprolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
EtoperidoneThe serum concentration of Bisoprolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
exisulindexisulind may decrease the antihypertensive activities of Bisoprolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Bisoprolol.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Bisoprolol.Approved
FenoldopamBisoprolol may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Bisoprolol.Approved
FenoterolBisoprolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
FentanylFentanyl may increase the bradycardic activities of Bisoprolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Bisoprolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Bisoprolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Bisoprolol.Experimental
Ferulic acidBisoprolol may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bisoprolol.Approved, Investigational
FingolimodBisoprolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bisoprolol.Approved, Withdrawn
FluconazoleThe metabolism of Bisoprolol can be decreased when combined with Fluconazole.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Bisoprolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Bisoprolol.Experimental
FluoxetineThe metabolism of Bisoprolol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Bisoprolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
FluvoxamineThe metabolism of Bisoprolol can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolBisoprolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Bisoprolol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Bisoprolol can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bisoprolol.Approved
FosphenytoinThe metabolism of Bisoprolol can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Bisoprolol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Bisoprolol can be increased when it is combined with Fusidic Acid.Approved
GalantamineGalantamine may increase the bradycardic activities of Bisoprolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bisoprolol.Approved
GitoformateBisoprolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideBisoprolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideBisoprolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBisoprolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBisoprolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneBisoprolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideBisoprolol may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburideBisoprolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Bisoprolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Bisoprolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Bisoprolol.Approved
GuanazodineBisoprolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineBisoprolol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational
GuanoclorBisoprolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzBisoprolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanBisoprolol may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe metabolism of Bisoprolol can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Bisoprolol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Bisoprolol.Experimental
HexamethoniumBisoprolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Bisoprolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Bisoprolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Bisoprolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Bisoprolol.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideBisoprolol may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydroxychloroquineThe metabolism of Bisoprolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Bisoprolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Bisoprolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Bisoprolol.Approved
IdelalisibThe serum concentration of Bisoprolol can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Bisoprolol.Approved, Investigational
ImatinibThe metabolism of Bisoprolol can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Bisoprolol.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Bisoprolol.Experimental
ImipramineThe metabolism of Bisoprolol can be decreased when combined with Imipramine.Approved
IndacaterolBisoprolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Bisoprolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Indapamide.Approved
IndenololBisoprolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Bisoprolol can be decreased when combined with Indinavir.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Bisoprolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Bisoprolol.Withdrawn
IndoraminBisoprolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanBisoprolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkBisoprolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Bisoprolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Bisoprolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Bisoprolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Bisoprolol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bisoprolol.Approved
IsoetarineBisoprolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Bisoprolol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Bisoprolol.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Bisoprolol can be decreased when combined with Isoniazid.Approved
IsoprenalineBisoprolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Bisoprolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Bisoprolol.Approved
ItraconazoleThe metabolism of Bisoprolol can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineBisoprolol may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Bisoprolol can be increased when it is combined with Ivacaftor.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Bisoprolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Bisoprolol.Investigational
KetoconazoleThe metabolism of Bisoprolol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Bisoprolol.Approved
LabetalolBisoprolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineBisoprolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideBisoprolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
Lanatoside CBisoprolol may increase the bradycardic activities of Lanatoside C.Experimental
LanreotideBisoprolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostBisoprolol may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Bisoprolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Bisoprolol.Approved, Investigational
LevodopaBisoprolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Bisoprolol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
LevosalbutamolBisoprolol may decrease the bronchodilatory activities of Levosalbutamol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Bisoprolol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bisoprolol.Approved, Vet Approved
LinsidomineBisoprolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Bisoprolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Bisoprolol.Experimental
LopinavirThe metabolism of Bisoprolol can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Bisoprolol can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Losartan.Approved
LovastatinThe metabolism of Bisoprolol can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
LucinactantBisoprolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
LuliconazoleThe serum concentration of Bisoprolol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Bisoprolol can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Bisoprolol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
MacitentanBisoprolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bisoprolol.Approved
MalathionMalathion may increase the bradycardic activities of Bisoprolol.Approved, Investigational
ManidipineBisoprolol may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Bisoprolol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bisoprolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Bisoprolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Bisoprolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bisoprolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Bisoprolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Bisoprolol.Approved, Investigational
MetahexamideBisoprolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Bisoprolol.Investigational, Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Methacholine.Approved
MethadoneThe metabolism of Bisoprolol can be decreased when combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Bisoprolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Bisoprolol.Approved
MethoserpidineBisoprolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Bisoprolol can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bisoprolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bisoprolol.Approved, Investigational
MethylergometrineBisoprolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Bisoprolol.Approved
MetildigoxinBisoprolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Bisoprolol.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Bisoprolol.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bisoprolol.Approved, Investigational
MetyrosineBisoprolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilBisoprolol may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineBisoprolol may increase the bradycardic activities of Midodrine.Approved
MidostaurinThe metabolism of Bisoprolol can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Bisoprolol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe serum concentration of Bisoprolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Bisoprolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bisoprolol.Approved
MirabegronThe metabolism of Bisoprolol can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Bisoprolol.Investigational
MitotaneThe serum concentration of Bisoprolol can be decreased when it is combined with Mitotane.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Bisoprolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Bisoprolol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Moexipril.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Bisoprolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Bisoprolol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Bisoprolol.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Bisoprolol.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational
MuzolimineBisoprolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bisoprolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Bisoprolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Bisoprolol.Approved
NadololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Bisoprolol.Approved
NaftopidilBisoprolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Bisoprolol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Bisoprolol can be decreased when combined with Nelfinavir.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Bisoprolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Bisoprolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Bisoprolol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Bisoprolol can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Bisoprolol.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Bisoprolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Bisoprolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Bisoprolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bisoprolol.Approved
NiguldipineBisoprolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Bisoprolol can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineBisoprolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bisoprolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bisoprolol.Approved
NitrendipineBisoprolol may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Bisoprolol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Bisoprolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bisoprolol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
ObinutuzumabBisoprolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Bisoprolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Bisoprolol.Approved, Investigational
OlaparibThe metabolism of Bisoprolol can be decreased when combined with Olaparib.Approved
OleandrinBisoprolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bisoprolol.Approved, Investigational
OlodaterolBisoprolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Bisoprolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Bisoprolol.Approved
OmapatrilatBisoprolol may increase the hypotensive activities of Omapatrilat.Investigational
OrciprenalineBisoprolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Bisoprolol.Vet Approved
OsimertinibThe serum concentration of Bisoprolol can be increased when it is combined with Osimertinib.Approved
OuabainBisoprolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Bisoprolol.Approved
OxprenololBisoprolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bisoprolol.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bisoprolol.Approved, Vet Approved
PalbociclibThe serum concentration of Bisoprolol can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
PanobinostatThe serum concentration of Bisoprolol can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Papaverine.Approved
ParaoxonParaoxon may increase the bradycardic activities of Bisoprolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Bisoprolol.Approved
PargylinePargyline may increase the hypotensive activities of Bisoprolol.Approved
ParoxetineThe metabolism of Bisoprolol can be decreased when combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Bisoprolol.Investigational
PasireotideBisoprolol may increase the bradycardic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Bisoprolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Bisoprolol can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumBisoprolol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bisoprolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Bisoprolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Bisoprolol.Approved
PeruvosideBisoprolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Bisoprolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Bisoprolol.Withdrawn
PhenobarbitalThe metabolism of Bisoprolol can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineBisoprolol may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bisoprolol.Withdrawn
PhentolamineBisoprolol may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
PhenylpropanolamineBisoprolol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Bisoprolol can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Bisoprolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Bisoprolol.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bisoprolol.Approved, Investigational
PirbuterolBisoprolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Bisoprolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Bisoprolol.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Bisoprolol.Withdrawn
Platelet Activating FactorBisoprolol may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideBisoprolol may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaBisoprolol may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Bisoprolol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Bisoprolol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Bisoprolol.Experimental, Investigational
PrazosinBisoprolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Bisoprolol can be decreased when combined with Primaquine.Approved
PrimidoneThe metabolism of Bisoprolol can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Bisoprolol.Approved
ProcaterolBisoprolol may decrease the bronchodilatory activities of Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Bisoprolol.Experimental
PromazineThe metabolism of Bisoprolol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Bisoprolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
PropafenoneThe serum concentration of Bisoprolol can be increased when it is combined with Propafenone.Approved
PropericiazinePropericiazine may increase the hypotensive activities of Bisoprolol.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Bisoprolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Bisoprolol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Bisoprolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Bisoprolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Bisoprolol.Experimental
ProscillaridinBisoprolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Bisoprolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Bisoprolol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Bisoprolol can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Bisoprolol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Bisoprolol.Approved
RanolazineThe metabolism of Bisoprolol can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Bisoprolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Bisoprolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bisoprolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Bisoprolol.Approved
RescinnamineBisoprolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Bisoprolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Bisoprolol.Approved, Experimental, Investigational
RifabutinThe metabolism of Bisoprolol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Bisoprolol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Bisoprolol can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Bisoprolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Bisoprolol.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Riociguat.Approved
RisperidoneBisoprolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineBisoprolol may decrease the bronchodilatory activities of Ritodrine.Approved, Investigational
RitonavirThe metabolism of Bisoprolol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabBisoprolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Bisoprolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Bisoprolol.Investigational, Withdrawn
RolapitantThe metabolism of Bisoprolol can be decreased when combined with Rolapitant.Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Bisoprolol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Bisoprolol.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Bisoprolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Bisoprolol.Approved
SafrazineSafrazine may increase the hypotensive activities of Bisoprolol.Withdrawn
SalbutamolBisoprolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Bisoprolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
SalmeterolBisoprolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Bisoprolol.Approved
SaprisartanBisoprolol may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Bisoprolol can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Bisoprolol.Approved, Investigational, Vet Approved
SelexipagBisoprolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Bisoprolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Bisoprolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Bisoprolol.Investigational
SertralineThe metabolism of Bisoprolol can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Bisoprolol.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Bisoprolol.Approved, Investigational
SilodosinBisoprolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SiltuximabThe serum concentration of Bisoprolol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Bisoprolol can be increased when it is combined with Simeprevir.Approved
SitaxentanBisoprolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Bisoprolol.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Bisoprolol.Approved
SpiraprilBisoprolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bisoprolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Bisoprolol.Investigational
St. John's WortThe serum concentration of Bisoprolol can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Bisoprolol can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Bisoprolol.Approved, Investigational
SufentanilBisoprolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bisoprolol.Approved
SulfisoxazoleThe metabolism of Bisoprolol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Bisoprolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Bisoprolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Bisoprolol.Experimental
TacrineTacrine may increase the bradycardic activities of Bisoprolol.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Bisoprolol.Approved, Investigational
TalinololBisoprolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinBisoprolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Bisoprolol.Investigational
TelaprevirThe metabolism of Bisoprolol can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Bisoprolol can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Telmisartan.Approved, Investigational
TemocaprilBisoprolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Bisoprolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Bisoprolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Bisoprolol.Vet Approved
TerazosinBisoprolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Bisoprolol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineBisoprolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bisoprolol.Approved
TerlipressinBisoprolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineBisoprolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Bisoprolol.Approved, Investigational, Withdrawn
TheodrenalineBisoprolol may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineBisoprolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Bisoprolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bisoprolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Bisoprolol.Approved
ThioridazineThe metabolism of Bisoprolol can be decreased when combined with Thioridazine.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bisoprolol.Approved
TiboloneBisoprolol may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Bisoprolol can be decreased when combined with Ticlopidine.Approved
TicrynafenBisoprolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Bisoprolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Bisoprolol.Investigational
TipranavirThe metabolism of Bisoprolol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
TocilizumabThe serum concentration of Bisoprolol can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Bisoprolol.Approved, Investigational
TolazamideBisoprolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineBisoprolol may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideBisoprolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Bisoprolol.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bisoprolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Bisoprolol.Approved
TolonidineBisoprolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Bisoprolol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Bisoprolol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bisoprolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bisoprolol.Experimental
TranylcypromineThe metabolism of Bisoprolol can be decreased when combined with Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Bisoprolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Bisoprolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Bisoprolol.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Bisoprolol.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Bisoprolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Bisoprolol.Vet Approved
TrichlormethiazideBisoprolol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bisoprolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
TrimazosinBisoprolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Bisoprolol.Approved, Investigational
TriptolideTriptolide may decrease the antihypertensive activities of Bisoprolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Bisoprolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Bisoprolol.Approved, Investigational
UnoprostoneBisoprolol may increase the hypotensive activities of Unoprostone.Approved
UrapidilBisoprolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bisoprolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bisoprolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Bisoprolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe metabolism of Bisoprolol can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Verapamil.Approved
VilanterolBisoprolol may decrease the bronchodilatory activities of Vilanterol.Approved
VincamineBisoprolol may increase the hypotensive activities of Vincamine.Experimental
VinpocetineBisoprolol may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Bisoprolol can be decreased when combined with Voriconazole.Approved, Investigational
XipamideBisoprolol may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Bisoprolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Bisoprolol can be decreased when combined with Ziprasidone.Approved
ZofenoprilBisoprolol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Bisoprolol.Withdrawn
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Yoshihiro Iwao, Katsuyuki Ookubo, Katsuhiro Okada, Kunihiro Minami, Shuichiro Yuasa, "Adhesive Pharmaceutical Preparation Containing Bisoprolol." U.S. Patent US20090169604, issued July 02, 2009.

US20090169604
General References
Not Available
External Links
Human Metabolome Database
HMDB14750
KEGG Drug
D02342
KEGG Compound
C06852
PubChem Compound
2405
PubChem Substance
46508844
ChemSpider
2312
BindingDB
25751
ChEBI
3127
ChEMBL
CHEMBL645
Therapeutic Targets Database
DAP000483
PharmGKB
PA448641
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Bisoprolol
ATC Codes
C07BB07 — Bisoprolol and thiazidesC09BX02 — Perindopril and bisoprololC07FB07 — Bisoprolol and other antihypertensivesC07AB57 — Bisoprolol, combinationsC07AB07 — Bisoprolol
AHFS Codes
  • 24:24.00 — Beta-adrenergic Blocking Agents
MSDS
Download (73.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedDiagnosticAbdominal Aortic Aneurysm Patients Under Surveillance1
0Unknown StatusPreventionPatients With Coronary Artery Disease Scheduled for by Pass Surgery1
1CompletedBasic ScienceHealthy Volunteers / Pharmacodynamics of Mirabegron1
1CompletedTreatmentFasting1
1CompletedTreatmentFed1
1CompletedTreatmentHealthy Volunteers2
1, 2Unknown StatusTreatmentIdiopathic Pulmonary Arterial Hypertension1
2TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Heart Failure, Unspecified1
2, 3CompletedPreventionCoronary Artery Disease / Diabetes Mellitus (DM) / Heart Failure, Unspecified1
3CompletedTreatmentChagas Cardiomyopathy / Chronic Heart Failure (CHF)1
3CompletedTreatmentHypertensive1
3RecruitingPreventionCancer, Breast / Cardiotoxicity1
4Active Not RecruitingTreatmentHypertension, Resistant to Conventional Therapy1
4Active Not RecruitingTreatmentPostural Orthostatic Tachycardia Syndrome (POTS)1
4CompletedHealth Services ResearchHypertensive / Metabolic Syndromes1
4CompletedPreventionAdverse Effects / Coronary Artery Atherosclerosis / Insulin resistance syndrome1
4CompletedSupportive CareHypertensive1
4CompletedTreatmentChronic Heart Failure (CHF)2
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentCongestive Heart Failure (CHF)1
4CompletedTreatmentHeart Failure, Unspecified / Ventricular Dysfunction, Left1
4CompletedTreatmentHypertensive3
4CompletedTreatmentHypertensive / Pharmacogenetics1
4CompletedTreatmentHypertensive / Type 2 Diabetes Mellitus1
4CompletedTreatmentUntreated Essential Hypertension1
4Not Yet RecruitingTreatmentPermanent Atrial Fibrillation1
4RecruitingTreatmentAcute Myocardial Infarction (AMI) / Non-ST Elevation Myocardial Infarction / ST Elevation Myocardial Infarction1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentHeart Failure, Unspecified1
4RecruitingTreatmentHypertension Resistant To Conventional Therapy1
4RecruitingTreatmentHypertensive1
4SuspendedTreatmentHeart Rate Control in ICD Patients With Heart Failure1
4TerminatedTreatmentAortic Valve Stenosis1
4Unknown StatusTreatmentHypertensive1
Not AvailableCompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedTreatmentClozapine-induced Sinustachycardia1
Not AvailableCompletedTreatmentMyocardial Ischemia1
Not AvailableRecruitingNot AvailableAortic Valve Stenosis / Hypertension,Essential / Impaired Renal Function / Secondary Hypertension1
Not AvailableRecruitingBasic ScienceArterial Hypertension / Osteopenia1
Not AvailableUnknown StatusNot AvailableHeart Failure, Unspecified1
Not AvailableUnknown StatusTreatmentChronic Heart Failure (CHF)1

Pharmacoeconomics

Manufacturers
  • Aurobindo pharma ltd
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Unichem pharmaceuticals (usa) inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral5 mg/1
Tablet, coatedOral10 mg/1
Tablet, coatedOral5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
TabletOral
Tablet, coatedOral
TabletOral10 mg
TabletOral5 mg
Tablet, film coatedOral
Prices
Unit descriptionCostUnit
Condylox 0.5% Gel 3.5 gm Tube304.93USD tube
Condylox 0.5% Solution 3.5ml Bottle143.4USD bottle
Condylox 0.5% gel97.73USD g
Zebeta 10 mg tablet3.6USD tablet
Zebeta 5 mg tablet3.6USD tablet
Bisoprolol fumarate 5 mg tablet1.78USD tablet
Bisoprolol fumarate 10 mg tablet1.24USD tablet
Bisoprolol-Hydrochlorothiazide 10-6.25 mg tablet1.19USD tablet
Bisoprolol-Hydrochlorothiazide 2.5-6.25 mg tablet1.19USD tablet
Bisoprolol-Hydrochlorothiazide 5-6.25 mg tablet1.19USD tablet
Apo-Bisoprolol 10 mg Tablet0.38USD tablet
Novo-Bisoprolol 10 mg Tablet0.38USD tablet
Pms-Bisoprolol 10 mg Tablet0.38USD tablet
Sandoz Bisoprolol 10 mg Tablet0.38USD tablet
Apo-Bisoprolol 5 mg Tablet0.23USD tablet
Novo-Bisoprolol 5 mg Tablet0.23USD tablet
Pms-Bisoprolol 5 mg Tablet0.23USD tablet
Sandoz Bisoprolol 5 mg Tablet0.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)100 °CPhysProp
water solubility2240 mg/LNot Available
logP1.87RECANATINI,M (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.0707 mg/mLALOGPS
logP2.3ALOGPS
logP2.2ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area59.95 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity92.15 m3·mol-1ChemAxon
Polarizability38.5 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9445
Blood Brain Barrier-0.9077
Caco-2 permeable+0.6149
P-glycoprotein substrateSubstrate0.7785
P-glycoprotein inhibitor INon-inhibitor0.807
P-glycoprotein inhibitor IINon-inhibitor0.7821
Renal organic cation transporterNon-inhibitor0.8568
CYP450 2C9 substrateNon-substrate0.8134
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6113
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9485
CYP450 3A4 inhibitorNon-inhibitor0.8373
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9766
Ames testNon AMES toxic0.9064
CarcinogenicityNon-carcinogens0.9267
BiodegradationNot ready biodegradable0.8962
Rat acute toxicity2.0089 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7877
hERG inhibition (predictor II)Non-inhibitor0.6611
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0109000000-564ffde4ea3f59c4126f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-2903000000-5e5b905ef2026aa7f011
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00xr-9800000000-99ce6ca7b3171d63af09
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9600000000-bfefc02f00a4439a34ba
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05fr-9500000000-4b91d206ced038eff35c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ab9-9400000000-dd6baeb57f900d719aa9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0209000000-0f37dcfed3fc1c82c470
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-5902000000-dae2a435db6b3ea664cd
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-05fr-9200000000-1cce569461a677bb6467
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0209000000-65dd49cd88f0ec134445
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00or-5709000000-360e67ed724045a9c01b

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzylethers
Direct Parent
Benzylethers
Alternative Parents
Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Dialkyl ethers / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Benzylether / Phenoxy compound / Phenol ether / Alkyl aryl ether / 1,2-aminoalcohol / Secondary alcohol / Dialkyl ether / Secondary amine / Secondary aliphatic amine / Ether
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
secondary alcohol, secondary amine (CHEBI:3127)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Breed JG, Ciampricotti R, Tromp GP, Valster FA, Lageweg E, Van Bortel LM: Quality of life perception during antihypertensive treatment: a comparative study of bisoprolol and enalapril. J Cardiovasc Pharmacol. 1992;20(5):750-5. [PubMed:1280737]
  2. Brouri F, Hanoun N, Mediani O, Saurini F, Hamon M, Vanhoutte PM, Lechat P: Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol. 2004 Feb 6;485(1-3):227-34. [PubMed:14757145]
  3. Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, Brodde OE: The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol. 2005 Dec 6;46(11):2111-5. Epub 2005 Nov 4. [PubMed:16325050]
  4. Lipworth BJ, Irvine NA, McDevitt DG: A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol. 1991;40(2):135-9. [PubMed:1676675]
  5. Mauz AB, Pelzer H: Beta-adrenoceptor-binding studies of the cardioselective beta blockers bisoprolol, H-I 42 BS, and HX-CH 44 BS to heart membranes and intact ventricular myocytes of adult rats: two beta 1-binding sites for bisoprolol. J Cardiovasc Pharmacol. 1990 Mar;15(3):421-7. [PubMed:1691366]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Brouri F, Hanoun N, Mediani O, Saurini F, Hamon M, Vanhoutte PM, Lechat P: Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol. 2004 Feb 6;485(1-3):227-34. [PubMed:14757145]
  2. Bruck H, Poller U, Lussenhop H, Ponicke K, Temme T, Heusch G, Philipp T, Brodde OE: Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study. Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):361-8. Epub 2004 Oct 23. [PubMed:15526107]
  3. Motomura S, Reinhard-Zerkowski H, Daul A, Brodde OE: On the physiologic role of beta-2 adrenoceptors in the human heart: in vitro and in vivo studies. Am Heart J. 1990 Mar;119(3 Pt 1):608-19. [PubMed:1968697]
  4. Brodde OE: Bisoprolol (EMD 33512), a highly selective beta 1-adrenoceptor antagonist: in vitro and in vivo studies. J Cardiovasc Pharmacol. 1986;8 Suppl 11:S29-35. [PubMed:2439795]
  5. Daul A, Johnston T, Reher M, Kruger M, Brodde OE: Differential haemodynamic effects induced by beta 1-(bisoprolol) or beta 2-(ICI 118,551) adrenoceptor blockade in man. J Hypertens Suppl. 1986 Dec;4(6):S99-102. [PubMed:2886573]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Horikiri Y, Suzuki T, Mizobe M: Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci. 1998 Mar;87(3):289-94. [PubMed:9523980]
  2. Horikiri Y, Suzuki T, Mizobe M: Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63(13):1097-108. [PubMed:9763205]
  3. Nozawa T, Taguchi M, Tahara K, Hashimoto Y, Igarashi N, Nonomura M, Kato B, Igawa A, Inoue H: Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol. 2005 Nov;46(5):713-20. [PubMed:16220080]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Horikiri Y, Suzuki T, Mizobe M: Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci. 1998 Mar;87(3):289-94. [PubMed:9523980]
  2. Horikiri Y, Suzuki T, Mizobe M: Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63(13):1097-108. [PubMed:9763205]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34